AI Roadmap for Digital Epilepsy Management

Use Case:

Definition of a feasibility and business plan to integrate AI into an existing epilepsy management platform with a focus on improving seizure detection prediction and therapy adherence through intelligent data processing.

Outcome:

TRL 9 reached: platform commercially available and operational; Business model for AI adoption defined and aligned with growth strategy; Clear vision for AI-based personalization in seizure prediction and treatment support; Strategic partnerships outlined with hospitals, pharma companies, and patient communities.

Ecosystem Support:

Supported by the StairwAI program; guidance from both technical and business mentors; leveraged feedback cycles to consolidate strategy and documentation.

AI Relevance:

This case illustrates the value of AI for digital therapeutics by: I) bridging commercially ready health tech with data-driven enhancement paths; II) preparing structured, ethical AI adoption in safety-critical applications; III) engaging cross-sector partnerships to fuel innovation; IV) emphasizing scalability of AI-based care in underserved populations

Summary:

MyEpi ApS, a Danish digital health company, is on a mission to become a global leader in epilepsy management. Its existing platform integrates smartwatch technology, real-time seizure detection algorithms, GPS-based caregiver alerts, and personalized medication reminders to empower patients and caregivers alike. Through its participation in the StairwAI Support Program, MyEpi developed a Feasibility Plan and a Business Model for AI adoption, laying the foundation for a future transformation of its services through artificial intelligence. The team envisions AI integration to improve the accuracy of seizure prediction, optimize medication scheduling, and enable fully personalized support. A risk-balanced data collection strategy was defined, with careful attention to ethical constraints and user burden. MyEpi also plans to collaborate with hospitals, neurologists, and pharmaceutical companies through pilot projects that support data-sharing frameworks. Social media engagement and partnerships with patient associations will further support dissemination and adoption. With the current platform already at TRL 9, MyEpi is poised to extend its functionalities by embedding AI into its core architecture, creating a powerful assistive tool for the millions affected by epilepsy worldwide.